Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $122 | In Stock | |
5 mg | $313 | In Stock | |
10 mg | $497 | In Stock | |
25 mg | $793 | In Stock | |
50 mg | $1,130 | In Stock | |
1 mL x 10 mM (in DMSO) | $323 | In Stock |
Description | Tovinontrine (IMR-687) (IMR-687) is a potent and selective inhibitor of phosphodiesterase-9 (PDE9), designed to target sickle cell disease treatment. It exhibits high efficacy, with IC 50 values of 8.19 nM and 9.99 nM for PDE9A1 and PDE9A2, respectively [1]. |
In vitro | Tovinontrine (IMR-687) (0.03-10 μM) treatment for 6 hours in erythroid K562 cells increases cGMP in a dose-dependent manner.[1] IMR-687 (0.1-10 μM) treatment in erythroid K562 cells for 72 hours induces hemoglobin (HbF) in a dose-dependent manner.[1] |
In vivo | Tovinontrine (IMR-687) (30 mg/kg/day; 30 days) resulted in a more than three-fold increase in the proportion of HbF+ F-cells (8.4% in the vehicle-treated group and 27.3% in the IMR-687 treated group), accompanied by a corresponding two-fold reduction in sickled red blood cells (56.3% in the vehicle-treated group and 24.4% in the IMR-687 treated group).[1] |
Alias | IMR-687 |
Molecular Weight | 394.47 |
Formula | C21H26N6O2 |
Cas No. | 2062661-53-2 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 90.0 mg/mL (228.2 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.